Example: Heart Attack

Search clinical trials for: Computer Algorithm

Total 3684 results

NCT01153672

Completed

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer
NCT01384448

Completed

Stress Echocardiography and Heart Computed Tomography (CT) Scan in Emergency Department Patients With Chest Pain

Coronary Artery Disease | Chest Pain | Angina Pectoris | Angina
NCT07510334

Recruiting

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8
NCT07301268

Recruiting

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Recurrent Astrocytoma, IDH-Mutant, Grade 4 | Recurrent Glioblastoma, IDH-Wildtype | Recurrent Gliosarcoma | Glioblastoma, IDH-Wildtype | Resectable Glioblastoma | Progressive Glioblastoma | Resectable Astrocytoma | Progressive Astrocytoma, IDH-Mutant, Grade 4 | Progressive Gliosarcoma
NCT07155317

Recruiting

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Unresectable Mucosal Melanoma | Advanced Cutaneous Melanoma | Metastatic Mucosal Melanoma | Advanced Mucosal Melanoma | Metastatic Acral Melanoma | Unresectable Acral Melanoma | Advanced Acral Melanoma
NCT06943664

Not yet recruiting

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8
NCT06724237

Recruiting

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic Large Cell Lymphoma, ALK-Negative | Follicular Helper T-Cell Lymphoma | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
NCT06572605

Recruiting

External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

Multiple Myeloma | Extramedullary Disease in Multiple Myeloma
NCT06439836

Recruiting

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma
NCT06203600

Recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8
NCT06132685

Recruiting

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

Meningioma | Low Grade Glioma | Malignant Brain Neoplasm | Malignant Brain Glioma
NCT02314169

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Stage IV Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Metastatic Anal Canal Carcinoma
NCT06521775

Completed

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma

Metastatic Adenoid Cystic Carcinoma
NCT01959672

Completed

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
NCT03801876

Recruiting

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
NCT04682158

Recruiting

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

Esophageal Adenocarcinoma
NCT02710734

Completed

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Urothelial Carcinoma of the Bladder
NCT00544830

Active, not recruiting

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Stage IV Prostate Adenocarcinoma AJCC v7 | PSA Level Greater Than Two
NCT06632977

Recruiting

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial (PREDICT)

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8
NCT04751409

Recruiting

Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities

Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
NCT06157099

Active, not recruiting

Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma

Pathologic Stage IIA Cutaneous Melanoma AJCC v8 | Pathologic Stage IIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
NCT02431702

Completed

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (DREaM)

Psychotic Disorders | Schizophrenia
NCT07128680

Recruiting

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Sarcomatoid Renal Cell Carcinoma
NCT06369610

Recruiting

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma
NCT06305598

Recruiting

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8
NCT03660826

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma | Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
NCT03793166

Active, not recruiting

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Viscera | Sarcomatoid Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Metastatic Malignant Neoplasm in the Soft Tissue
NCT05050162

Suspended

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Advanced Head and Neck Squamous Cell Carcinoma | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma | Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 | Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
NCT06094842

Withdrawn

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma
NCT05419583

Completed

Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction (TARGET-Type 2)

Myocardial Infarction Type 2
NCT02356159

Completed

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Leukemia
NCT07463807

Not yet recruiting

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Refractory Multiple Myeloma | Recurrent Multiple Myeloma
NCT07061964

Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8 | Muscle Invasive Bladder Urothelial Carcinoma
NCT06675136

Recruiting

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

Metastatic Gastric Adenocarcinoma | Clinical Stage IVB Gastric Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Peritoneum
NCT02567422

Active, not recruiting

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Head and Neck Carcinoma of Unknown Primary
NCT03502733

Active, not recruiting

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Lymphoma | Unresectable Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
NCT05053152

Active, not recruiting

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study (NRG PROMETHEAN)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Prostate Ductal Adenocarcinoma | Oligometastatic Prostate Carcinoma | Prostate Intraductal Carcinoma
NCT05642143

Recruiting

Deep Phenotyping of Bone Disease in Type 2 Diabetes and Relations to Diabetic Neuropathy

Type 2 Diabetes | Osteoporosis | Diabetic Neuropathy Peripheral | Bone Disease | Autonomic Neuropathy, Diabetic
NCT01652196

Completed

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer
NCT01851369

Completed

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

NSCLC | Solid Tumors | Lymphomas | Granulosa Cell Ovarian Cancer | Metastatic Colon Carcinoma
NCT04144023

Recruiting

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Breast Ductal Carcinoma In Situ
NCT02444741

Completed

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Malignant Solid Neoplasm | Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7
NCT07529483

Recruiting

Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms (ERASE-Chemo)

Pancreatic Cystic Neoplasm
NCT06639074

Recruiting

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Primary Peritoneal Clear Cell Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Advanced Fallopian Tube Carcinoma | Advanced Ovarian Carcinoma | Advanced Primary Peritoneal Carcinoma | Advanced Ovarian Clear Cell Adenocarcinoma
NCT06572618

Recruiting

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma
NCT06126276

Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm
NCT06058663

Recruiting

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic Cholangiocarcinoma
NCT05904080

Recruiting

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma
NCT05890352

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
NCT05786040

Recruiting

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Polymorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

Search clinical trials for: Computer Algorithm

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations